15 July 2013 Oryzon obtains orphan designation for ORY-1001 for the treatment of Acute Myeloid Leukemia from the European Medicines Agency
7 January 2014 ORYZON Initiates Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia
16 January 2014 ORYZON receives approval from MHRA to initiate Clinical Development of ORY-1001, a Novel LSD1 Inhibitor, in Patients with Acute Myeloid Leukemia in the United Kingdom
2 October 2014 Oryzon presentation at the B-debate 50 YEARS OF HISTONE ACETYLATION Barcelona Conference on Epigenetics and Cancer celebrated in CaixaForum, Barcelona.